A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128
Recruiting
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/21/2025
Locations: Baptist Cancer Center, Memphis, Tennessee +4 locations
Conditions: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Register for Updates
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
NCT00804154
Recruiting
This study will examine the safety of giving the experimental drug, resiniferatoxin (RTX), to treat severe pain in patients with advanced cancer. RTX is a chemical extracted from a cactus-like plant. It is similar to capsaicin, the active ingredient in hot pepper. RTX has relieved pain and reduced the need for pain medication in several animal experiments. It works by destroying nerves that transmit pain information. People at least 18 years of age with severe pain from advanced cancer at or be... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Intractable Pain, Palliative Care
Register for Updates
Natural History and Development of Spondyloarthritis
NCT01422694
Recruiting
Background: - Spondyloarthritis (SpA) is a group of bone and joint disorders that may cause back and joint pain and stiffness. In some cases, SpA can lead to abnormal bone growth affecting the joints and spine. Some patients have SpA without ever developing these growths, while others develop them after only a few years. Researchers are interested in studying people with SpA and their relatives to determine which people are more likely to develop more severe conditions. Objectives: - To ident... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Arthritis, Spondylitis, Ankylosing
Register for Updates
Combining MyoCI With Memory Reactivation to Improve Motor Recovery After Stroke
NCT04312269
Recruiting
This study will examine the combination of myoelectric computer interface (MyoCI) training with targeted memory reactivation (TMR) in chronic stroke survivors. The study aims to determine whether this training-plus-sleep combination will generalize to improve arm motor function over an extended training protocol in stroke survivors.
Gender:
ALL
Ages:
Between 21 years and 100 years
Trial Updated:
08/21/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Stroke
Register for Updates
Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults
NCT07095231
Recruiting
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of STX-S in adults who have previously received a primary series and at least one booster with an authorized or licensed SARS-CoV-2 parenteral vaccine. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating three dose levels of STX-S. A sample size of 60 participants (20 participants per dose cohort) is anticipated. The primary objective is to evaluate the safety and... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/21/2025
Locations: University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York +2 locations
Conditions: COVID-19
Register for Updates
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310
Recruiting
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Local Institution - 0347, Birmingham, Alabama +328 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627
Recruiting
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
08/21/2025
Locations: Usa Health Mitchell Cancer Institute, Mobile, Alabama +73 locations
Conditions: Ovarian Cancer
Register for Updates
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
NCT06849791
Recruiting
This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/21/2025
Locations: Acpru /Id# 266649, Grayslake, Illinois
Conditions: Healthy Volunteer
Register for Updates
Long-Covid-19 Alleviation Through Learning Mindfulness Study
NCT07140094
Recruiting
This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance. Here the investigators are studying whether a mindfulness intervention can help reduce stress, reduce Long COVID symptoms, and improve quality of life among people living with Long COVID. The mindfulness intervention is a ser... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Columbia University, New York, New York
Conditions: Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, COVID Long-Haul
Register for Updates
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
NCT06792500
Recruiting
This is a parallel arm non-randomized dose-escalation, open-label basket exploratory phase 1 clinical trial where Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS) and Leber's hereditary optic neuropathy-Plus (LHON-Plus) participants will undergo simultaneous enrollment in two disease-based arms and receive daily oral doses of glycerol tributyrate to assess its safety and potential for efficacy using clinical, biochemical, and molecular evidence. This study will utiliz... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/21/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Register for Updates
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
NCT01581424
Recruiting
The investigators will perform a study with two major components. The first is a natural history study of untreated Fabry patients. This study component will detail kidney microscopic structural changes in Fabry patients before starting enzyme replacement therapy and will correlate these changes with kidney function, including glomerular filtration rate and urinary albumin excretion rate. The investigators will perform studies on samples obtained at baseline, or before enzyme replacement therapy... Read More
Gender:
ALL
Ages:
Between 1 year and 75 years
Trial Updated:
08/21/2025
Locations: University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Fabry Disease
Register for Updates
Stone and Laser Therapies Post-Market Study (SALT)
NCT06982235
Recruiting
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g., transurethral or percutaneous access routes) or benign prostatic hyperplasia (BPH) treatment.
Gender:
ALL
Ages:
All
Trial Updated:
08/21/2025
Locations: University of Miami Hospital, Miami, Florida
Conditions: Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Register for Updates